Loading...
Early experience with remdesivir in SARS-CoV-2 pneumonia
At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients h...
Na minha lista:
| Udgivet i: | Infection |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7229436/ https://ncbi.nlm.nih.gov/pubmed/32418190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s15010-020-01448-x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|